Hospitalizations Associated with Malignant Neoplasia and in Situ Carcinoma in the Anus and Penis in Men and Women During a 5-year Period (2009-2013) in Spain: An Epidemiological Study

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2017 Jul 15

PMID 28708948

Citations 2

Authors

Noelia Lopez

Angel Gil-de-Miguel

Raquel Pascual-Garcia

Ruth Gil-Prieto

Affiliations

Soon will be listed here.

Abstract

Background: Approximately 40,000 new cases of anal cancer and 26,000 new cases of penile cancer occurred in 2012 worldwide. Human Papillomavirus (HPV) infection is responsible for 88.3% and 33.0% of these cancers, respectively. The aim of this study was to describe the hospital burden associated with malignant neoplasm (MN) and in situ carcinoma (ISC) in the anus and penis in Spain from 2009 to 2013.

Methods: This observational, retrospective study used discharge information obtained from the national surveillance system for hospital data, Conjunto Mínimo Básico de Datos, provided by the Ministry of Health.

Results: We found 3,668 hospitalizations due to MN and ISC in the anus for both genders, and more than 55% of these hospitalizations occurred in men and were associated with a lower median age of hospitalization (p < 0.001), higher average length of hospital stay (ALOS) (p = 0.0032), higher hospitalization costs (p < 0.001) and higher hospitalization rate (2.141 per 100,000 males aged > 14 y old and 1.604 per 100,000 women aged > 14 y old, p < 0.001) than in women. During the same period, 4,156 hospitalizations due to MN and ISC of the penis were registered. The hospitalization rate was 4.320 per 100,000 males aged > 14 y old. The hospitalization rate due to MN and ISC in the anus in males increased significantly during this period (p = 0.048).

Conclusion: Our study provides relevant information about the hospital burden of anal and penile MN and ISC in Spain. This information could be useful for cost effectiveness analysis of universal HPV vaccination and for future HPV vaccination impact monitoring in Spain, and for other countries of similar socioeconomic status.

Citing Articles

Hospitalization burden associated with anus and penis neoplasm in Spain (2016-2020).

Fernandez-Alonso V, Gil-Prieto R, Amado-Anton-Pacheco M, Hernandez-Barrera V, Gil-de-Miguel A Hum Vaccin Immunother. 2024; 20(1):2334001.

PMID: 38557433 PMC: 10986764. DOI: 10.1080/21645515.2024.2334001.

Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.

de la Fuente J, Hernandez Aguado J, San Martin M, Ramirez Boix P, Cedillo Gomez S, Lopez N Hum Vaccin Immunother. 2019; 15(7-8):1949-1961.

PMID: 30698488 PMC: 6746536. DOI: 10.1080/21645515.2018.1560770.

References

Alemany L, Cubilla A, Halec G, Kasamatsu E, Quiros B, Masferrer E . Role of Human Papillomavirus in Penile Carcinomas Worldwide. Eur Urol. 2016; 69(5):953-61. DOI: 10.1016/j.eururo.2015.12.007. View

Keeping S, Tempest M, Stephens S, Carroll S, Nugent K, ODwyer S . The cost of anal cancer in England: retrospective hospital data analysis and Markov model. BMC Public Health. 2014; 14:1123. PMC: 4232734. DOI: 10.1186/1471-2458-14-1123. View

Johnson L, Madeleine M, Newcomer L, Schwartz S, Daling J . Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004; 101(2):281-8. DOI: 10.1002/cncr.20364. View

Sudenga S, Ingles D, Pierce Campbell C, Lin H, Fulp W, Messina J . Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study. Eur Urol. 2015; 69(1):166-73. PMC: 4670812. DOI: 10.1016/j.eururo.2015.05.032. View

Giuliano A, Kreimer A, de Sanjose S . The beginning of the end: vaccine prevention of HPV-driven cancers. J Natl Cancer Inst. 2015; 107(6):djv128. DOI: 10.1093/jnci/djv128. View

Palefsky J, Giuliano A, Goldstone S, Moreira Jr E, Aranda C, Jessen H . HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011; 365(17):1576-85. DOI: 10.1056/NEJMoa1010971. View

Giuliano A, Palefsky J, Goldstone S, Moreira Jr E, Penny M, Aranda C . Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011; 364(5):401-11. PMC: 3495065. DOI: 10.1056/NEJMoa0909537. View

Gil-Prieto R, Pascual-Garcia R, Walter S, Alvaro-Meca A, Gil-de-Miguel A . Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE study. Hum Vaccin Immunother. 2016; 12(7):1900-5. PMC: 4964827. DOI: 10.1080/21645515.2016.1143577. View

Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S . Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016; 4(9):e609-16. DOI: 10.1016/S2214-109X(16)30143-7. View

10.

Stanley M . HPV vaccination in boys and men. Hum Vaccin Immunother. 2014; 10(7):2109-11. PMC: 4186028. DOI: 10.4161/hv.29137. View

11.

Alemany L, Saunier M, Alvarado-Cabrero I, Quiros B, Salmeron J, Shin H . Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2014; 136(1):98-107. PMC: 4270372. DOI: 10.1002/ijc.28963. View

12.

Van Damme P, Meijer C, Kieninger D, Schuyleman A, Thomas S, Luxembourg A . A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016; 34(35):4205-4212. DOI: 10.1016/j.vaccine.2016.06.056. View

13.

Serrano B, de Sanjose S, Tous S, Quiros B, Munoz N, Bosch X . Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015; 51(13):1732-41. DOI: 10.1016/j.ejca.2015.06.001. View

14.

Islami F, Ferlay J, Lortet-Tieulent J, Bray F, Jemal A . International trends in anal cancer incidence rates. Int J Epidemiol. 2016; 46(3):924-938. DOI: 10.1093/ije/dyw276. View

15.

Miralles-Guri C, Bruni L, Cubilla A, Castellsague X, Bosch F, de Sanjose S . Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol. 2009; 62(10):870-8. DOI: 10.1136/jcp.2008.063149. View

16.

Gil-Prieto R, Ester P, Alvaro-Meca A, Rodriguez M, de Miguel A . The burden of hospitalizations for anus and penis neoplasm in Spain (1997-2008). Hum Vaccin Immunother. 2012; 8(2):201-7. DOI: 10.4161/hv.18388. View

17.

Cortes Bordoy J . [Vaccination against the human papilloma virus. Consensus statement 2011 of the scientific Spanish societies]. Semergen. 2013; 38(5):312-26. DOI: 10.1016/j.semerg.2012.04.016. View

18.

Peiro S, Librero J . [The quality assessment from the minimum basic hospital discharge data set]. Rev Neurol. 1999; 29(7):651-61. View

19.

Gil A, San-Martin M, Gil R, Hernandez V, Ribes J, Gonzalez A . Burden of hospital admissions for cervical cancer in Spain during 1999-2002. Hum Vaccin. 2007; 3(6):276-80. DOI: 10.4161/hv.4875. View

20.

Pitisuttithum P, Velicer C, Luxembourg A . 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. Expert Rev Vaccines. 2015; 14(11):1405-19. DOI: 10.1586/14760584.2015.1089174. View